logo
Plus   Neg
Share
Email

Pentair Boosts FY19 Earnings Guidance - Quick Facts

While reporting financial results for the second quarter, Pentair plc (PNR) on Tuesday raised its earnings and adjusted earnings guidance for the full-year 2019, while maintaining sales growth guidance. The company also initiated third-quarter outlook.

For fiscal 2019, the company now projects earnings of about $2.13 per share and adjusted earnings of about $2.35 per share. The company now expects sales to be about flat to up 1 percent on a reported basis and about flat to down 1 percent on a core basis from last year.

The company reiterates its full year 2019 sales guidance of up approximately 1 to 2 percent on a reported basis and approximately flat to up 1 percent on a core basis

Previously, the company expected earnings from continuing operations in a range of about $2.04 to $2.09 per share and on an adjusted basis in the range of about $2.30 to $2.35 per share. It also projected full year 2019 sales to be up about 1 to 2 percent on a reported basis and about flat to up 1 percent on a core basis.

On average, 16 analysts polled by Thomson Reuters expect the company to report earnings of $2.31 per share on sales growth of 1.4 percent to $3.01 billion for the year. Analysts' estimates typically exclude special items.

For the third quarter, the company projects earnings in a range of about $0.50 to $0.52 per share and on an adjusted basis in the range of about $0.54 to $0.56 per share on sales of about flat to up 2 percent on a reported basis and about down 1 to 3 percent on a core basis from last year.

The Street is looking for earnings of $0.57 per share on sales growth of 4.5 percent to $743.26 million for the third quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said that the current state of the COVID-19 pandemic in the U.S. is "really not good." The U.S. is the country worst-affected by the coronavirus and has recently seen a surge in coronavirus infections as lockdown restrictions are eased. Granules Pharmaceuticals, Inc. recalled twelve (12) lots of type 2 diabetes medication Metformin hydrochloride Extended-Release, in the form of oral film-coated tablets, for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Palantir Technologies Inc., the Silicon Valley big data analytics company that has handled U.S. government's certain sensitive projects, said it has confidentially filed documents with the Securities and Exchange Commission to go public. In a statement, the company said the proposed public listing of its Class A common stock is expected to take place after the SEC completes its review process.
Follow RTT